IPP Bureau
Bliss GVS Pharma posts Q1 FY26 PAT higher at Rs. 43.03 Cr
By IPP Bureau - August 01, 2025
Bliss GVS Pharma has reported total income of Rs. 242.92 crores during the period ended June 30, 2025
iPHEX 2025 to showcase India’s pharmaceutical and healthcare power on Sept 4-6, 2025
By IPP Bureau - August 01, 2025
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
Bio-Rad names Rajat Mehta as EVP - Global Commercial Operations
By IPP Bureau - August 01, 2025
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
By IPP Bureau - August 01, 2025
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Roche presents new Alzheimer’s research at AAIC 2025
By IPP Bureau - July 31, 2025
Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
Bristol Myers Squibb appoints Cristian Massacesi as EVP, Chief Medical Officer, and Head of Development
By IPP Bureau - July 31, 2025
He most recently served as Chief Medical Officer of AstraZeneca and Alexion
Trixeo Aerosphere receives positive EU CHMP opinion as first inhaled medicine with near-zero GWP
By IPP Bureau - July 31, 2025
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
Roche updates on Elevidys gene therapy for Duchenne muscular dystrophy in EU
By IPP Bureau - July 31, 2025
Elevidys is currently the only approved gene therapy that targets the root cause of Duchenne
Bristol Myers Squibb and Bain Capital launch biotech company NewCo
By IPP Bureau - July 31, 2025
NewCo’s pipeline includes five investigational medicines
Imfinzi granted Priority Review and Breakthrough Therapy Designation in US
By IPP Bureau - July 31, 2025
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Fortis and Agilus expand rapid genomic testing capabilities
By IPP Bureau - July 31, 2025
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Maziar Mike Doustdar appointed President and CEO of Novo Nordisk
By IPP Bureau - July 31, 2025
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
Asahi Kasei Life Science to construct new plant for Planova virus removal filters
By IPP Bureau - July 31, 2025
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
Aurobindo to acquire Lannett Company for Rs. 2,185 Cr
By IPP Bureau - July 31, 2025
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Wallace Pharmaceuticals appoints Chinmaya Mohanty as VP & Head – Human Resources
By IPP Bureau - July 30, 2025
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
